McDermott Represents Prime Therapeutics in its $1.35 Billion Acquisition of Magellan RX - McDermott Will & Emery

McDermott Represents Prime Therapeutics in its $1.35 Billion Acquisition of Magellan RX


International law firm McDermott Will & Emery represented Prime Therapeutics LLC, a pharmacy benefits manager, in its $1.35 billion definitive agreement with Centene Corporations to acquire Magellan RX Management, a division of Magellan Health, Inc., a next-generation pharmacy organization that is delivering meaningful solutions to the people they serve.

  • The transaction was announced on May 5, 2022, and subject to regulatory approvals, is expected to close in late 2022.
  • Combining Prime’s fully transparent and channel-independent model with Magellan Rx’s industry-leading portfolio of medical pharmacy solutions is expected to create a new specialty drug management model — one that uniquely aligns and integrates with providers and harnesses the patient and provider relationship to meet patients where they are in their care journey.
  • The McDermott corporate team was led by Mark Mihanovic and Diego Gomez-Cornejo. The relationship partner for Prime Therapeutics is Jeremy Earl. The regulatory team was led by Mimi Alexandre and Steve Wu and Dan Powers provided antitrust support.
  • Read Prime’s press release here.

About McDermott

McDermott Will & Emery partners with leaders around the world to fuel missions, knock down barriers and shape markets. Our team works seamlessly across practices, industries and more than 20 locations to deliver highly effective solutions that propel success. More than 1,200 lawyers strong, we bring our personal passion and legal prowess to bear in every matter for our clients and the people they serve.

Media Contacts